Table 3.
Cumulative Costs, Life Expectancy and Cost-Effectiveness by Intention-to-Treat (Base Case) and by Per-Protocol Analysis
| Scenario | Catheter Ablation* | Drug Therapy* | Difference* | Incremental Cost Effectiveness Ratio | Probability of Cost-Effectiveness |
||
|---|---|---|---|---|---|---|---|
| $50,000 | $100,000 | $150,000 | |||||
| Intention-To-Treat Analysis (Base Case) | |||||||
| Lifetime Costs, USD | 151,877 (133,394 – 157,359) |
136,361 (116,183 – 142,242) |
15,516 (−2,963 – 35,512) |
-- | -- | -- | -- |
| QALYs | 11.01 (10.82 – 11.20) |
10.74 (10.55 – 10.93) |
0.27 (0.07 – 0.47) |
$57,893 per QALY | 41% | 75% | 88% |
| LYs | 12.63 (12.41 – 12.85) |
12.54 (12.32 – 12.76) |
0.08 (−0.14 – 0.32) |
$183,318 per LY | 17% | 33% | 45% |
|
| |||||||
| Per-Protocol Analysis | |||||||
| Lifetime Costs, USD | 148,105 (129,978 – 154,137) |
106,667 (87,237 – 113,009) |
41,438 (22,830 – 60,759) |
-- | -- | -- | -- |
| QALYs | 10.70 (10.50 – 10.90) |
10.13 (9.95 – 10.31) |
0.57 (0.30 – 0.84) |
$72,835 per QALY | 12% | 81% | 97% |
| LYs | 12.24 (12.01 – 12.47) |
11.95 (11.73 – 12.16) |
0.29 (−0.02 – 0.61) |
$141,832 per LY | 1% | 24% | 52% |
*
Estimates expressed as mean (95% confidence interval).
Abbreviations: LY – life year; QALY – quality-adjusted life year; USD – United States dollar.